161 related articles for article (PubMed ID: 10421544)
1. The effect of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guided interstitial therapy for localized carcinoma of the prostate.
Whittington R; Broderick GA; Arger P; Malkowicz SB; Epperson RD; Arjomandy B; Kassaee A
Int J Radiat Oncol Biol Phys; 1999 Jul; 44(5):1107-10. PubMed ID: 10421544
[TBL] [Abstract][Full Text] [Related]
2. Timing of computed tomography-based postimplant assessment following permanent transperineal prostate brachytherapy.
Prestidge BR; Bice WS; Kiefer EJ; Prete JJ
Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1111-5. PubMed ID: 9539566
[TBL] [Abstract][Full Text] [Related]
3. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy.
Hinerman-Mulroy A; Merrick GS; Butler WM; Wallner KE; Allen Z; Adamovich E
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1367-82. PubMed ID: 15275722
[TBL] [Abstract][Full Text] [Related]
4. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation.
Gelblum DY; Potters L; Ashley R; Waldbaum R; Wang XH; Leibel S
Int J Radiat Oncol Biol Phys; 1999 Aug; 45(1):59-67. PubMed ID: 10477007
[TBL] [Abstract][Full Text] [Related]
5. Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy.
Kucway R; Vicini F; Huang R; Stromberg J; Gonzalez J; Martinez A
J Urol; 2002 Jun; 167(6):2443-7. PubMed ID: 11992054
[TBL] [Abstract][Full Text] [Related]
6. Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer.
Merrick GS; Butler WM; Galbreath RW; Lief JH
Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):41-8. PubMed ID: 11516849
[TBL] [Abstract][Full Text] [Related]
7. Outpatient ultrasound-guided palladium 103 brachytherapy for localized adenocarcinoma of the prostate: a preliminary report of 434 patients.
Sharkey J; Chovnick SD; Behar RJ; Perez R; Otheguy J; Solc Z; Huff W; Cantor A
Urology; 1998 May; 51(5):796-803. PubMed ID: 9610594
[TBL] [Abstract][Full Text] [Related]
8. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
9. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
Kollmeier MA; Stock RG; Stone N
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
[TBL] [Abstract][Full Text] [Related]
10. Minimally invasive treatment for localized adenocarcinoma of the prostate: review of 1048 patients treated with ultrasound-guided palladium-103 brachytherapy.
Sharkey J; Chovnick SD; Behar RJ; Perez R; Otheguy J; Rabinowitz R; Steele J; Webster C; Donohue M; Solc Z; Huff W; Cantor A
J Endourol; 2000 May; 14(4):343-50. PubMed ID: 10910150
[TBL] [Abstract][Full Text] [Related]
11. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma.
Stock RG; Stone NN; DeWyngaert JK; Lavagnini P; Unger PD
Cancer; 1996 Jun; 77(11):2386-92. PubMed ID: 8635111
[TBL] [Abstract][Full Text] [Related]
12. Preimplant factors affecting postimplant CT-determined prostate volume and the CT/TRUS volume ratio after transperineal interstitial prostate brachytherapy with 125I free seeds.
Sugawara A; Nakashima J; Kunieda E; Nagata H; Asakura H; Oya M; Shigematsu N
Radiat Oncol; 2010 Sep; 5():86. PubMed ID: 20875137
[TBL] [Abstract][Full Text] [Related]
13. Optimum timing for image-based dose evaluation of 125I and 103PD prostate seed implants.
Yue N; Chen Z; Peschel R; Dicker AP; Waterman FM; Nath R
Int J Radiat Oncol Biol Phys; 1999 Nov; 45(4):1063-72. PubMed ID: 10571216
[TBL] [Abstract][Full Text] [Related]
14. Preimplant factors affecting prostate D90 after transperineal interstitial prostate brachytherapy with loose (125)I seeds.
Sugawara A; Nakashima J; Kunieda E; Nagata H; Mizuno R; Takeda A; Seki S; Shiraishi Y; Kouta R; Oya M; Shigematsu N
Keio J Med; 2012; 61(3):89-94. PubMed ID: 23018491
[TBL] [Abstract][Full Text] [Related]
15. A nomogram to compensate for intraoperative prostate edema during transperineal brachytherapy.
Potters L; Wang XH; Yamada Y
Tech Urol; 2000 Jun; 6(2):99-103. PubMed ID: 10798808
[TBL] [Abstract][Full Text] [Related]
16. Effect of prostate size and isotope selection on dosimetric quality following permanent seed implantation.
Merrick GS; Butler WM; Dorsey AT; Lief JH
Tech Urol; 2001 Sep; 7(3):233-40. PubMed ID: 11575521
[TBL] [Abstract][Full Text] [Related]
17. Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy.
Potters L; Torre T; Ashley R; Leibel S
J Clin Oncol; 2000 Mar; 18(6):1187-92. PubMed ID: 10715287
[TBL] [Abstract][Full Text] [Related]
18. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
19. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
Ho AY; Burri RJ; Cesaretti JA; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):16-22. PubMed ID: 19289266
[TBL] [Abstract][Full Text] [Related]
20. Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy.
Mabjeesh NJ; Chen J; Stenger A; Matzkin H
Urology; 2007 Sep; 70(3):548-53. PubMed ID: 17905113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]